WO2017024317A3 - Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles - Google Patents
Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles Download PDFInfo
- Publication number
- WO2017024317A3 WO2017024317A3 PCT/US2016/046087 US2016046087W WO2017024317A3 WO 2017024317 A3 WO2017024317 A3 WO 2017024317A3 US 2016046087 W US2016046087 W US 2016046087W WO 2017024317 A3 WO2017024317 A3 WO 2017024317A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- protein degradation
- targeted protein
- bifunctional molecules
- induce targeted
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000017854 proteolysis Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Abstract
La présente invention concerne des composés bifonctionnels qui servent de fragments induisant la dégradation de protéine. La présente invention concerne également des acides nucléiques, des polypeptides, des cellules, et des procédés pour la dégradation ciblée, hautement régulée, de protéines par utilisation des composés bifonctionnels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562202076P | 2015-08-06 | 2015-08-06 | |
US62/202,076 | 2015-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017024317A2 WO2017024317A2 (fr) | 2017-02-09 |
WO2017024317A3 true WO2017024317A3 (fr) | 2017-04-27 |
Family
ID=56990946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/046087 WO2017024317A2 (fr) | 2015-08-06 | 2016-08-08 | Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017024317A2 (fr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
CN107257800B (zh) | 2014-12-23 | 2020-06-30 | 达纳-法伯癌症研究所股份有限公司 | 通过双功能分子诱导靶蛋白降解的方法 |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
KR20230119040A (ko) * | 2015-01-20 | 2023-08-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법 |
WO2017007612A1 (fr) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
WO2017030814A1 (fr) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine |
CN109475528B (zh) | 2016-04-22 | 2022-01-11 | 达纳-法伯癌症研究所股份有限公司 | 用于egfr降解的双功能分子和使用方法 |
WO2017197055A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
WO2017197036A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
WO2018064589A1 (fr) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Dégradation ciblée de protéines à l'aide d'une ubiquitine ligase e3 mutante |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
KR102564201B1 (ko) | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
WO2019043208A1 (fr) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | Dihydroquinolinones |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
WO2019084026A1 (fr) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation |
EP3710002A4 (fr) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | Agents de dégradation et dégrons pour dégradation protéique ciblée |
JP2021514012A (ja) * | 2018-02-20 | 2021-06-03 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfrの分解誘導剤およびその使用法 |
WO2019164932A1 (fr) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci |
JP2021514400A (ja) * | 2018-02-20 | 2021-06-10 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfrの阻害剤およびその使用法 |
US11802132B2 (en) | 2018-02-23 | 2023-10-31 | Dana-Farber Cancer Institute, Inc. | Small molecules for inducing selective protein degradation and uses thereof |
KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
WO2019204354A1 (fr) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Composés spirocycliques |
LT3784663T (lt) | 2018-04-23 | 2023-10-25 | Celgene Corporation | Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui |
EP3578561A1 (fr) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spirocomposés |
JP2021527137A (ja) | 2018-06-13 | 2021-10-11 | アンフィスタ セラピューティクス リミテッド | Rpn11を標的化するための二機能性分子 |
WO2019238886A1 (fr) | 2018-06-13 | 2019-12-19 | University Of Dundee | Molécules bifonctionnelles pour le ciblage de l'usp14 |
KR20210020107A (ko) | 2018-06-13 | 2021-02-23 | 암피스타 테라퓨틱스 엘티디 | UchL5 표적화를 위한 이중작용성 분자 |
JP2021529807A (ja) * | 2018-07-05 | 2021-11-04 | アイカーン スクール オブ メディスン アット マウント シナイ | タンパク質チロシンキナーゼ6(ptk6)分解/破壊化合物および使用方法 |
WO2020041387A1 (fr) * | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Modifications de domaine de dégradation pour la régulation spatio-temporelle de nucléases guidées par arn |
WO2020041331A1 (fr) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives |
CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
US11691984B2 (en) | 2018-10-12 | 2023-07-04 | The Scripps Research Institute | Compounds and methods for DCAF-mediated protein degradation |
WO2020102195A1 (fr) | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Isoindolinones substituées |
US20220089589A1 (en) * | 2019-01-07 | 2022-03-24 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS |
CN113365699A (zh) * | 2019-02-02 | 2021-09-07 | 石药集团中奇制药技术(石家庄)有限公司 | 靶向泛素化降解brd4蛋白化合物及其制备方法和应用 |
CA3127501A1 (fr) * | 2019-02-08 | 2020-08-13 | University Of Florida Research Foundation, Incorporated | Agents therapeutiques et methodes de traitement |
CN113747925A (zh) | 2019-03-21 | 2021-12-03 | 科迪亚克生物科学公司 | 胞外囊泡缀合物及其用途 |
WO2020191369A1 (fr) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
WO2020200291A1 (fr) * | 2019-04-02 | 2020-10-08 | Cullgen (Shanghai) , Inc. | Composés et méthodes de traitement de cancers |
US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
BR112022011827A2 (pt) | 2019-12-20 | 2022-08-30 | C4 Therapeutics Inc | Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção |
IL294150A (en) | 2019-12-23 | 2022-08-01 | Kymera Therapeutics Inc | Smarca joints and their uses |
KR20220166797A (ko) | 2020-03-05 | 2022-12-19 | 씨4 테라퓨틱스, 인코포레이티드 | Brd9의 표적화된 분해를 위한 화합물 |
WO2021222138A1 (fr) * | 2020-04-27 | 2021-11-04 | Development Center For Biotechnology | Composés pour la dégradation de la protéine ras mutante |
WO2021237100A1 (fr) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Procédés d'administration ciblée de vésicules extracellulaires dans le poumon |
WO2022066928A2 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
WO2022068933A1 (fr) * | 2020-09-30 | 2022-04-07 | Cullgen (Shanghai) , Inc. | Composés et méthodes de traitement de maladies |
CN116615429A (zh) * | 2020-10-14 | 2023-08-18 | 珃诺生物医药科技(杭州)有限公司 | 用于靶向蛋白降解的方法和组合物 |
TW202237095A (zh) | 2020-12-03 | 2022-10-01 | 德商艾斯巴赫生物有限公司 | Alc1抑制劑及與parpi之協同性 |
EP4259144A1 (fr) * | 2020-12-09 | 2023-10-18 | Kymera Therapeutics, Inc. | Agents de dégradation de smarca et leurs utilisations |
CA3208313A1 (fr) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Composes d'isoindolinone |
WO2023283130A1 (fr) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Dérivés d'isoquinoléine en tant que modulateurs d'egfr mutants et leurs utilisations |
WO2023006097A1 (fr) * | 2021-07-30 | 2023-02-02 | 海创药业股份有限公司 | Composé hétérocyclique chimère bifonctionnel et son utilisation en tant qu'agent de dégradation du récepteur des androgènes |
WO2023172889A1 (fr) * | 2022-03-07 | 2023-09-14 | The University Of North Carolina At Chapel Hill | Utilisation de modificateurs épigénétiques chimiques pour moduler l'expression génique |
WO2023213833A1 (fr) | 2022-05-02 | 2023-11-09 | Eisbach Bio Gmbh | Utilisation d'inhibiteurs d'alc1 et synergie avec parpi |
WO2023242176A1 (fr) * | 2022-06-13 | 2023-12-21 | Julius-Maximilians-Universität Würzburg | Protéines de fusion de transposase destinées à être utilisées dans une thérapie cellulaire et génique |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
WO2024081913A1 (fr) * | 2022-10-14 | 2024-04-18 | 76Bio, Inc. | Protéines de fusion bifonctionnelles à double spécificité pour dégradation médiée par l'ubiquitine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029827A2 (fr) * | 2001-10-01 | 2003-04-10 | Bioimage A/S | Methode amelioree permettant de detecter des interactions entre des constituants cellulaires presents dans des cellules vivantes intactes et d'extraire des informations quantitatives se rapportant auxdites interactions par nouvelle repartition de fluorescence |
WO2014159312A2 (fr) * | 2013-03-14 | 2014-10-02 | University Of Florida Research Foundation, Incorporated | Nouvelles agrégation et toxicité diminuées d'alpha-1 antitrypsine mutante à anticorps à chaîne unique |
US20140335539A1 (en) * | 2011-12-05 | 2014-11-13 | Medical & Biological Laboratories Co., Ltd. | Method for detecting protein-protein interaction |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (fr) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6517889B1 (en) | 2001-11-26 | 2003-02-11 | Swaminathan Jayaraman | Process for coating a surface of a stent |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
-
2016
- 2016-08-08 WO PCT/US2016/046087 patent/WO2017024317A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029827A2 (fr) * | 2001-10-01 | 2003-04-10 | Bioimage A/S | Methode amelioree permettant de detecter des interactions entre des constituants cellulaires presents dans des cellules vivantes intactes et d'extraire des informations quantitatives se rapportant auxdites interactions par nouvelle repartition de fluorescence |
US20140335539A1 (en) * | 2011-12-05 | 2014-11-13 | Medical & Biological Laboratories Co., Ltd. | Method for detecting protein-protein interaction |
WO2014159312A2 (fr) * | 2013-03-14 | 2014-10-02 | University Of Florida Research Foundation, Incorporated | Nouvelles agrégation et toxicité diminuées d'alpha-1 antitrypsine mutante à anticorps à chaîne unique |
Non-Patent Citations (7)
Title |
---|
G. E. WINTER ET AL: "Phthalimide conjugation as a strategy for in vivo target protein degradation", SCIENCE, vol. 348, no. 6241, 19 June 2015 (2015-06-19), pages 1376 - 1381, XP055328122, ISSN: 0036-8075, DOI: 10.1126/science.aab1433 * |
JAN KRÖNKE ET AL: "Lenalidomide induces ubiquitination and degradation of CK1[alpha] in del(5q) MDS", NATURE, vol. 523, no. 7559, 9 July 2015 (2015-07-09), United Kingdom, pages 183 - 188, XP055336278, ISSN: 0028-0836, DOI: 10.1038/nature14610 * |
M. SEKIGUCHI ET AL: "An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR", PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 24, no. 11, 6 September 2011 (2011-09-06), GB, pages 811 - 817, XP055336205, ISSN: 1741-0126, DOI: 10.1093/protein/gzr045 * |
PHILIP P CHAMBERLAIN ET AL: "Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs", NATURE STRUCTURAL AND MOLECULAR BIOLOGY, vol. 21, no. 9, 10 August 2014 (2014-08-10), US, pages 803 - 809, XP055336279, ISSN: 1545-9993, DOI: 10.1038/nsmb.2874 * |
ROBERS MATT ET AL.: "Fluorescent labeling of proteins in living cells using the FKBP12 (F36V) tag", CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY, vol. 75, no. 3, March 2009 (2009-03-01), pages 207 - 224, XP002762671, ISSN: 1552-4930 * |
WANG T ET AL: "Specific Interaction of Type I Receptors of the TGF-beta Family with the Immunophilin FKBP-12", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 265, 29 July 1994 (1994-07-29), pages 674 - 676, XP002173914, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.7518616 * |
WANG XIAO-SONG ET AL: "Characterization of KRAS rearrangements in metastatic prostate cancer", CANCER DISCOVERY,, vol. 1, no. 1, 1 June 2011 (2011-06-01), pages 35 - 43, XP009167682, ISSN: 2159-8290, DOI: 10.1158/2159-8274.CD-10-0022 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017024317A2 (fr) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017024317A3 (fr) | Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
TWI799368B (zh) | 抗tl1a抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途 | |
WO2015109124A3 (fr) | Agents immunomodulateurs | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
EP3741848A3 (fr) | Variantes de protéases et polynucléotides les codant | |
WO2015196128A3 (fr) | Molécules d'acide nucléique alternatives et leurs utilisations | |
WO2016107818A8 (fr) | Compositions et procédés de glycosylation de protéines | |
WO2015196130A3 (fr) | Molécules d'acide nucléique alternatives et leurs utilisations | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
EP3773727A4 (fr) | Petites molécules bifonctionnelles pour cibler la dégradation sélective de protéines circulantes | |
WO2018081592A3 (fr) | Compositions et procédés pour la production de composés | |
WO2016066756A3 (fr) | Variants de protéase et polynucléotides les codant | |
WO2016066757A3 (fr) | Variants de protéase et polynucléotides les codant | |
EP3234200A4 (fr) | Compositions et procédés d'appauvrissement ciblé, d'enrichissement et de séparation d'acides nucléiques utilisant les protéines du système cas/crispr | |
WO2015112886A3 (fr) | Protéines de liaison et leurs procédés d'utilisation | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
WO2015089511A3 (fr) | Molécules d'acides nucléiques modifiés et leurs utilisations | |
WO2016065349A8 (fr) | Arn non codants courts régulateurs de protéines (sprrna) et procédés d'utilisation | |
BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
EP3543335A3 (fr) | Protéines de fusion d'intéine solubles et procédés de purification de biomolécules | |
EP3964575A3 (fr) | Variants d'alpha-amylase et polynucléotides codant pour ces derniers | |
WO2015161267A3 (fr) | Anticorps monoclonaux humanisés et chimériques contre cd99 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16770585 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16770585 Country of ref document: EP Kind code of ref document: A2 |